Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | unknown | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03646968 | Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study(SAVE) | unknown | Phase 2 | 43 | Yongchang ZhangOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05338619 | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy(PLATINUM) | unknown | Phase 2 | 77 | Sung Yong LeeOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05962021 | Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation | unknown | Phase 2 | 126 | Peking University People's HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT04396457 | Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | unknown | Phase 2 | 50 | National Hospital Organization Nagoya Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04211090 | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC(CAP-BRAIN) | unknown | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05394233 | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | unknown | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03254004 | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | unknown | Phase 2 | 70 | Samsung Medical CenterOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453423 | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2020 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation(Geber) | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 3, 2018 | clinicaltrials |
| NCT03127319 | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | unknown | Phase 2 | 40 | Affiliated Hospital of Hebei UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02788058 | A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy | unknown | Phase 2 | 76 | First People's Hospital of HangzhouOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT00339586 | First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene | unknown | Phase 2 | 40 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 21, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Mar 28, 2024source: clinicaltrials